Dr. Luke Discusses PD-1 Plus IDO Inhibitors in Melanoma

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.

There are early-phase data with pembrolizumab (Keytruda) and epacadostat showing that adding the IDO inhibitor improved the response rate to pembrolizumab monotherapy from 40% to 55%, explains Luke. There was no increased toxicity observed in this combination.

A phase III trial investigating this combination compared with a placebo-controlled pembrolizumab monotherapy has completed accrual. According to Luke, this combination could change the standard of care for patients with melanoma.

<<< View more from the World Congress of Melanoma